Table I.
TSPAN17 levels are associated with clinicopathologic and genetic features of patients with glioblastoma multiforme.
| TSPAN17 levels (mRNA) | ||||
|---|---|---|---|---|
| Clinicopathological characteristics | Low level n=12 | High level n=41 | rs | P-value |
| Ages (years)b | 0.313 | 0.019a | ||
| 40–49 | 4 | 7 | ||
| 50–60 | 5 | 25 | ||
| >60 | 3 | 9 | ||
| Sex | 0.114 | 0.31 | ||
| Male | 7 | 20 | ||
| Female | 5 | 21 | ||
| Tumor size (cm) | 0.632 | 0.0009a | ||
| <5 cm | 7 | 9 | ||
| ≥5 cm | 5 | 32 | ||
| WHO grade | 0.554 | 0.0013a | ||
| I–II | 6 | 7 | ||
| III | 5 | 10 | ||
| IV | 1 | 24 | ||
| IDH status | 0.701 | 0.001a | ||
| Wild-type | 10 | 33 | ||
| Mutant | 2 | 8 | ||
| MGMT status | 0.254 | 0.045a | ||
| Methylated | 7 | 18 | ||
| Unmethylated | 5 | 23 | ||
| 1p 19q status | 0.198 | 0.122 | ||
| Non-codeletion | 4 | 20 | ||
| Codeletion | 8 | 21 | ||
| TERT | 0.107 | 0.33 | ||
| Wild-type | 6 | 19 | ||
| Mutant | 6 | 22 | ||
| ATRX | 0.821 | <0.001a | ||
| Wild-type | 5 | 3 | ||
| Mutant | 7 | 38 | ||
Values in bold indicate P<0.05.
a
P<0.05.
b
The age classification of patients was according to Zhang et al (46). ATRX, ATP-dependent helicase; IDH, isocitrate dehydrogenase; MGMT, O-6-methylguanine-DNA methyltransferase; TERT, telomerase reverse transcriptase; TSPAN17, tetraspanin 17; WHO, World Health Organization.